Circadian rhythms exert powerful influence on various aspects of human physiology and behavior. Here, we tested changes of human cerebral cortex excitability over the course of the day with transcranial magnetic stimulation (TMS). At different times of the day, intracortical and corticospinal excitability of the primary motor cortex (M1) was evaluated in 15 healthy subjects by TMS of left M1. While motor thresholds, short-interval intracortical inhibition and facilitation and input/output curves remained unchanged, we found that a specific form of g-aminobutyric acid (GABA)--mediated intracortical inhibition, revealed by long-interval intracortical inhibition and cortical silent periods, progressively decreased during the course of the day. Additional experiments demonstrated that morning inhibition persisted irrespective of previous sleep or sleep deprivation. Corticotropin-releasing hormone (CRH) infusions in the evening lead to morning cortisol levels but did not restore levels of morning inhibition, whereas suppression of endogenous CRH release by repeated oral dexamethasone intake over 24 h prevented morning inhibition. The findings suggest a specific modulation of GABAergic motor cortex inhibition within the circadian cycle, possibly linked to the CRH system, and may indicate a neurobiological basis for variable neuroplasticity over the course of the day.
Introduction
Human physiology and behavior is largely influenced by circadian rhythms. A roughly 24-h cycle modulates brain activity, hormone production, body temperature, cell regeneration, besides other biological activities. Irregularities of the circadian rhythm are often attributed to modern life and lead to jet lag, shift work disorder or sleep disorders (AASM 2005) . On the other hand, many neuropsychiatric diseases show circadian fluctuations of their symptomatology, such as affective disorders (Adrien 2002), epilepsies (Pung and Schmitz 2006) , or movement disorders (Paulus and Trenkwalder 2006) . This makes circadian changes of cerebral activity an interesting focus of neuropsychiatric research for clinicians as well as for basic neuroscientists. Much of this research aims at elucidating the neurobiological relation between sleep and cerebral functions. However, little is known so far about the circadian influences on the cerebral cortex during wakefulness.
The present study was designed to examine circadian changes of human cerebral cortex physiology with transcranial magnetic stimulation (TMS) over the course of the day in awake and normally acting healthy humans. TMS offers a broad array of measures of motor cortical excitability, which covers various aspects of neuronal functions, such as axon excitability, and distinct forms of inhibitory and excitatory synaptic excitability (Chen 2000) . Previous TMS work suggests that large changes in cortical excitability overtime may be normal for an individual subject, particularly in the silent period duration (Koski et al. 2005) , and showed increases in cortical excitability over the day, at least for certain chronotypes (Tamm et al. 2009 ), whereas other TMS measures seem to remain unchanged (Doeltgen and Ridding 2010) . Here, we aimed to elucidate these partly inconsistent data by systematically testing the complete range of TMS measurements at multiple times of the day, after sleep and sleep deprivation, and with pharmaco-hormonal interventions.
Materials and Methods

Subjects
Fifteen healthy young volunteers (10 men; mean age 27 ± 5 years; age range 20--31 years) gave their written informed consent to participate in the study. None of them had a circadian rhythm or sleep disorder, as evaluated by a certified specialist for neurology experienced in sleep medicine (NL). According to the German version of the Morningness--Eveningness Questionnaire (D-MEQ) (Griefahn 2002) , all participants were-regarding their chronobiology-intermediate types, moderate morning or moderate evening types. None was a definite morning or evening type. Subjects were used to have regular sleep of approximately 7--8 h per night and had no disruption of their sleep/wake rhythm during the 3 weeks before the experiments. They were instructed not to take any naps and were not allowed to ingest any alcohol, caffeine, nicotine, or other stimulants 1 day before and on the days of the experiments. All subjects were consistent right-handers according to the Edinburgh Handedness Inventory (Oldfield 1971) . Experimental procedures were approved by the Ethics Committee of the University of Goettingen and by the German Federal Institute for Drugs and Medical Devices (Bundesinstitut fu¨r Arzneimittel und Medizinprodukte [BfArM] ), and the study was performed according to the ethical standards laid down in the Declaration of Helsinki. Figure 1 illustrates the course of the main and all control experiments. All 15 subjects participated in the main experiment (Fig. 1A) , where we tested motor cortex excitability with single-and paired-pulse TMS at 3 different times in the course of 1 day (morning: 8 AM; midday: 2 PM, and evening: 8 PM). Different subgroups of the 15 subjects participated in 4 control experiments. Seven subjects (4 men; mean age 26 ± 4 years; age range 21--31 years) had additional TMS measurements the evening before the main experiment followed by a normal night sleep (Fig. 1B: control experiment #1). In 5 subjects (3 men; mean age 23 ± 2 years; age range 20--24 years), we performed additional TMS measurements the next morning after the day of the main experiments and a night of complete sleep deprivation (Fig. 1C: control experiment #2). Five subjects (all men; mean age 24 ± 2 years; age range 21--26 years) participated in a corticotropin-releasing hormone (CRH) test at 8 PM ( Fig. 1D : control experiment #3) and 6 subjects (all men; mean age 24 ± 2 years; age range 21--26 years) in a 24-h dexamethasone suppression test (Fig. 1E : control experiment #4), on days different to the main experiment. The reason for not studying women in the last 2 control experiments lies in the fact that approval by the German Federal Institute for Drugs and Medical Devices (BfArM) would have been given only with absolutely secure contraception due to possible harmful effects on pregnancy from the study medication. This was considered too difficult when setting up the experimental design. Also because of the knowledge on changes in cortical excitability within the menstrual cycle in women (Smith et al. 1999 (Smith et al. , 2002 , we tried to reduce this confound by studying only men in some of the control experiments.
Experimental Procedures
TMS Measurements of Cortical Excitability
In the main experiment, we tested the following parameters with TMS to the left M1 at all 3 time points in the course of the day: resting motor threshold (RMT) and active motor threshold (AMT), the TMS intensity to evoke motor evoked potential (MEP) of approximately 1-mV peakto-peak amplitude (SI1mV), input/output (I/O) curves, short-interval intracortical inhibition and intracortical facilitation (SICI/ICF), longinterval intracortical inhibition (LICI), active MEP during moderate tonic activation of the target muscle, and the cortical silent period (CSP). In all protocols, single-or paired-pulse TMS was applied at 0.25 Hz with variations in the repetition rate of ± 10%. RMT, AMT, and SI1mV were determined at the beginning of each experiment and are considered as global measures of corticospinal excitability (Chen 2000; Abbruzzese and Trompetto 2002) , which probably reflect neuronal membrane excitability, as they are increased under voltage-gated sodium channel blocker medication (Ziemann et al. 1996) . RMT was defined as the minimal output of the stimulator that induced a reliable MEP ( >50 lV in amplitude) in at least 5 of 10 consecutive trials in the relaxed first dorsal interosseus (FDI) muscle of the right hand, and AMT was defined as the lowest stimulus intensity at which 5 of 10 consecutive stimuli elicited reliable MEP ( >200 lV in amplitude) in the tonically contracted FDI (Rothwell et al. 1999) . I/O curves of MEP amplitudes elicited by increasing TMS intensities serve as an index of excitability of larger neuronal populations. Similar to motor thresholds, the I/O curve depends on neuronal membrane excitability because its slope is decreased by sodium and calcium channel blockers. However, synaptic mechanisms are involved additionally, as it is modulated by drugs influencing the c-aminobutyric acid (GABA)ergic and the adrenergic system (Boroojerdi et al. 1999 ) and can also be modulated by the glutamatergic system (Di Lazzaro et al. 2003) . I/O curves were measured with 3 different stimulus intensities (110%, 120%, and 140% RMT), each with 10 pulses, and a mean was calculated for each intensity. SICI/ICF was studied using a paired-pulse TMS protocol (Kujirai et al. 1993) . SICI/ICF reflects excitability of inhibitory and excitatory cortical interneurons, and since inhibition is enhanced and facilitation diminished by GABAergic (predominantly GABA(A)) and antiglutamatergic substances but not influenced by ion channel blockers (Ziemann et al. 1996 (Ziemann et al. , 1998 Chen et al. 1997; Liepert et al. 1997) , it may reflect primarily the activity of the glutamatergic and GABAergic circuits in the motor cortex. SICI/ICF was measured with a protocol of single-and paired-pulse TMS given through the same stimulating coil, and the effect of the first (conditioning) stimulus on the second (test) stimulus was investigated (Kujirai et al. 1993 ). To avoid floor or ceiling effects, the intensity of the conditioning stimulus was set to 80% AMT. The test--stimulus intensity was adjusted to SI1mV. SICI/ICF was measured with interstimulus intervals (ISIs) of 2, 4, 7, 9, and 12 ms. The control condition (test pulse alone) and each of the conditioning-test pairs were tested 15 times, and conditions were applied in randomized order. The mean amplitude of the conditioned MEP at each ISI was expressed as a percentage of the mean size of the Figure 1 . Experimental design. In the main experiment, cortical excitability was tested with a broad array of TMS measurements in 15 healthy subjects at 3 different times during the course of 1 day (A). In control experiments #1 and #2, evening and morning measurements were compared after a night of sleep and sleep deprivation in 7 and 5 subjects, respectively, who also participated in the main experiment (B,C). Control experiment #3 tested the effect of an infusion of 100-lg CRH in the evening in a subgroup of 5 subjects (D) and control experiment #4 compared TMS measurements before and during a dexamethasone suppression test in 6 subjects of the main experiment (E). unconditioned test pulse. Like SICI/ICF, LICI can also be tested with a paired-TMS protocol. Here, 2 suprathreshold stimuli are applied with ISIs of 50, 100, 150, and 200 ms (Valls-Sole et al. 1992; Nakamura et al. 1997) . The intensity of both stimuli was set to the relatively low value of 110% RMT in order to avoid floor effects. The control condition (first pulse alone) and each of the paired stimuli were tested 15 times, and conditions were applied in randomized order. LICI was taken as the mean percentage inhibition of conditioned MEP at ISIs of 50, 100, 150, and 200 ms. At the end of each session, 10 pulses with 120% RMT were applied during moderate tonic contraction of the FDI (approximately 30--50% of maximal voluntary contraction). The CSPs were determined in rectified and averaged electromyogram (EMG) traces with a prestimulus period of 100 ms. CSP (in ms) was measured from the TMS stimulus artifact to the point where the signal reached the amplitude of the mean prestimulus EMG activity again for >5 ms. While spinal inhibition contributes to the early part of the CSP, the late part ( >100 ms) originates in supraspinal structures, most likely the motor cortex (Fuhr et al. 1991; Inghilleri et al. 1993; Chen et al. 1999) . In contrast to SICI, LICI and CSP are thought to involve GABA(B)-receptor activity. CSPs were shown to be increased by intrathecal administration of GABA(B)-agonist baclofen (Siebner et al. 1998) or by the GABA reuptake inhibitor tiagabine, whereas LICI was also increased by tiagabine (Werhahn et al. 1999) . The observation that LICI inhibits SICI (Sanger et al. 2001 ) is consistent with the hypothesis that the former reduces the latter through presynaptic GABA(B) receptors.
To further elucidate the effects observed in the main experiment, we performed a series of control experiments with a small number of subjects, all of whom had also participated in the main experiment ( Fig. 1B --E). Since the main results were found in CSP and LICI, and CSP is a very robust and reproducible parameter, we focused only on CSP measurements in the control experiments #3 and #4. However, all other parameters as described above were also measured in control experiments #1 and #2. In all control experiments, the CSP was determined as described for the main experiment. The first 2 control experiments were performed to exclude unspecific arousal effects due to repeated TMS measurements (control experiment #1) and prolonged wakefulness (control experiment #2), respectively, but not to look explicitly at the effects of sleep and sleep deprivation itself. Therefore, they were only performed in a small number of subjects and without further quantification of sleep and wakefulness, for example, polysomnography or wakefulness tests. In the first control experiment, the duration of the mean CSP obtained on the evening (8 PM) before the main experimental day and a full night sleep was compared with values obtained at the next morning. In the second control experiment, additional measurements of the CSP obtained from a session on the morning (8 AM) after the main experimental day and a night of complete sleep deprivation were compared with values obtained on the evening before. In a third control experiment, we were interested whether the observed effects were linked to cortisol plasma levels. Thus, we determined the CSP and plasma cortisol levels in the evening on days separate to the main experiment and applied 100-lg human corticorelin (CRH Ferring, Ferring Arzneimittel) as an intravenous infusion to the left arm. Corticorelin infusion is known to increase plasma cortisol levels rapidly without penetrating the blood brain barrier (Martins et al. 1996) . We repeated CSP and plasma cortisol measurements 30 and 60 min after the infusion. Finally, in the fourth control experiment, we were interested in a link between endogenous CRH levels and our findings on CSP decrease during the day. We therefore performed a 36-h experiment with repeated CSP and plasma cortisol measurements at mornings (8 AM) and evenings (8 PM) of 2 consecutive days and orally administered 2 mg dexamethasone (Dexamethason-ratiopharm, ratiopharm GmbH) 4 times and every 6 h beginning at 12 PM on the first day.
Plasma Cortisol Concentrations
In the main experiment as well as in the third and fourth control experiments, plasma cortisol levels were determined in every subject and at each time point of TMS measurements before and after TMS. Blood samples were taken from an intravenous cannula from the left arm.
EMG Data Acquisition
During the experiments, subjects were comfortably seated in a reclining chair with mounted head and arm rests. Surface EMG was recorded from the FDI of the right hand through a pair of Ag--AgCl surface electrodes in a belly-tendon montage. Raw signals were amplified, band-pass filtered (3 Hz--3 kHz), digitized with a micro 1401 AD converter (Cambridge Electronic Design) controlled by Signal Software (Cambridge Electronic Design, version 2.13), and stored on a personal computer for offline analysis. Complete relaxation was controlled through auditory and visual feedback of EMG activity. TMS was performed by using 2 Magstim 200 stimulators via a bistim module (all TMS devices manufactured by the Magstim Company). The coil was held tangentially to the skull over the left M1 with the handle pointing posterolaterally at a 45°angle to the sagittal plane. This orientation of the induced electrical field is thought to be optimal for a predominantly transsynaptic mode of activation of the corticospinal system (Di Lazzaro et al. 1998) . At the beginning of each session, the optimal position of the TMS coil over the left M1 for eliciting MEP in the resting hand muscle was assessed. The site was marked with a skin marker to ensure that the coil was held in the correct position throughout the experiment, and TMS measurements were performed as described above.
Data Analyses
For the main experiment, we performed separate analyses of variance (ANOVAs) for repeated measurements for each TMS measure (SI1mV, RMT, AMT, I/O curve, SICI/ICF, LICI, and CSP), by using mean values from each subject as the dependent variable. In addition to the factor ''time of day'' (3 levels: 8 AM, 2 PM, and 8 AM), the ANOVA model included the factor ''intensity'' (3 levels: 100%, 120%, and 140% RMT) for I/O curves or ''ISI'' (5 levels: 2, 4, 7, 9, and 12 ms) for SICI/ICF or the factor ISI (4 levels: 50, 100, 150, and 200 ms) when LICI was analyzed. For LICI, a mean amount of inhibition (mean LICI, a mean of all 4 intervals) was calculated individually for each subject and each time point during the day for further analyses. Pearson's correlation coefficient was used to examine the relationship between CSP and LICI changes over the course of the day.
A mean was calculated of the cortisol plasma concentration values before and after TMS for each time point. This mean was entered into a one-factorial ANOVA for repeated measurements with the factor time of day (3 levels: 8 AM, 2 PM, and 8 AM). Pearson's correlation coefficient was also used to examine the relationship between the 2 TMS parameters and mean cortisol plasma concentrations over the course of the day.
In the first and second control experiments, we compared evening CSP duration with values obtained at the next morning using pairedsamples 2-tailed t-tests. For the third control experiment, we entered mean CSP duration values and plasma cortisol concentrations in 2 separate ANOVAS with the factor ''time'' (3 levels: before, 30 min, and 60 min after CRH infusion). Likewise, for the fourth control experiment, we entered mean CSP duration values and plasma cortisol concentrations in 2 separate ANOVAS with the factor time (4 levels: first morning, first evening, second morning, and second evening).
For all analyses, the Greenhouse--Geisser method was used when necessary to correct for nonsphericity. Conditional on significant F values in ANOVAs, paired-samples 2-tailed t-tests were used for post hoc analysis. Since the protocols were tested primarily by an ANOVA, corrections for multiple comparisons for post hoc t-test that aim to characterize significant findings from a previously performed ANOVA were not necessary. A P value of <0.05 was considered significant for all statistical analyses. Data are reported as mean ± standard error of the mean (SEM).
Results
Main Experiment
The duration of CSP and the amount of LICI critically depended on the time of day ( Fig. 2A,B) . This was indicated by separate ANOVAs on mean CSP and LICI values, which demonstrated significant main effects for the factor time of day (CSP: F 2,28 = 10.12, P < 0.001 and LICI: F 2,28 = 5.94, P = 0.007). For LICI, apart from an inherent main effect of the factor ISI (F 3,42 = 3.24, P = 0.032), ANOVA showed no significant interaction for the factors time of day and ISI. Further analyses of the main effects revealed a progressive reduction of CSP and LICI over the course of the day. Morning, midday, and evening values were 175 ± 5, 162 ± 5.0, and 158 ± 5.0 ms for CSP duration and 38 ± 5%, 59 ± 11%, and 74 ± 14% of unconditioned response for mean LICI, respectively. Post hoc t-test confirmed that mean CSP duration progressively decreased when morning and midday measurements were compared (t = 3.18, df = 14, P = 0.007), as well as when morning and evening measurements were compared (t = 3.66, df = 14, P = 0.003). Comparison between midday and evening measures of CSP did not reveal significantly different values. Post hoc t-test on mean LICI values demonstrated that the amount of inhibition also progressively decreased when morning and midday measurements were compared (t = 2.38, df = 14, P = 0.03), as well as when morning and evening measurements were compared (t = 3.13, df = 14, P = 0.007), while the comparison of midday and evening values revealed a decrease of marginal significance (t = 2.13, df = 14, P = 0.05). We also found a positive correlation between the decrease of CSP and the decrease of mean LICI: subjects who had the largest decrease of CSP from morning to evening also showed the greatest reduction of mean LICI from morning to evening (Pearson's correlation: r = 0.63, P = 0.012, Fig. 3 ). These circadian effects on CSP and LICI were the only ones of significance in the main experiment, since all other ANOVAs on SI1mV, RMT, AMT, I/O curves, and SICI/ICF did not results in significant main effects of the factor time of day (Fig. 4) . Plasma cortisol concentration showed a decrease over the course of the day (F 2,28 = 58.8, P < 0.001), as expected. Mean plasma cortisol in the morning (8 AM) was 216.4 ng/mL, at midday (2 PM) 112.5 ng/mL, and in the evening (8 PM) 61.1 ng/mL. However, these changes did not correlate with changes in CSP or LICI (Pearson's correlation: r = 0.2, P > 0.1).
Control Experiments
Comparing evening and morning CSP values from the first control experiment with a full night sleep (Fig. 5A) showed that mean CSP duration significantly increased from 156 ± 7 ms in the evening to 172 ± 5 ms the next morning (t = 2.58, df = 6, P = 0.042).
Equally, mean CSP values from the second control experiment with a night of sleep deprivation (Fig. 5B ) significantly increased from 158 ± 6 ms in the evening to 175 ± 9 ms the next morning (t = 3.1, df = 4, P = 0.036). All other TMS parameters did not show significant differences between evening and morning values of both experiments.
In the third control experiment, CRH infusion at 8 PM did not lead to changes in CSP duration (Fig. 6, lower panel) . Mean CSP was 132 ± 7 ms before, 132 ± 7 ms 30 min after, and 132 ± 14 ms 60 min after CRH infusion. ANOVAs did not reveal a significant main effect for the factor time for CSP but demonstrated a significant main effect of time for plasma cortisol levels (F 2,6 = 53.4, P < 0.001). Following CRH infusion mean plasma cortisol levels significantly increased from 47 ng/mL before CRH infusion to 134 ng/mL at 30 min and to 184 ng/mL at 60 min after CRH infusion (Fig. 6 , upper panel; post hoc t-tests; before vs. 30 min: t = 4.6, df = 4, P = 0.019; 30 vs. 60 min: t = 5.1, df = 4, P = 0.015; before vs. 60 min: t = 14.4, df = 4, P = 0.001). In the fourth control experiment, ANOVA demonstrated significant main effects of time for both measures, duration of CSP (F 3,15 = 11.3, P < 0.001), and plasma cortisol concentration (F 3,15 = 44.8, P < 0.001). On the first day of the dexamethasone experiment and before Figure 2 . Circadian changes of GABA-mediated cortical excitability. Two TMS parameters of cortical inhibition, the duration of CSP (A) and the amount of LICI (B) consecutively decreased during the course of the day. CSP significantly decreased from 175 ± 5 ms in the morning to 162 ± 5 ms at midday and 158 ± 5 in the evening. Mean LICI significantly decreased from 38 ± 5% in the morning to 59 ± 11% at midday and 74 ± 14% of unconditioned response in the evening. Data are shown as absolute values for CSP and in percentage of the unconditioned response for LICI at different ISIs (mean ± SEM, n 5 15). dexamethasone application CSP duration showed, as in the main experiment, a significant decrease from morning with 147 ± 13 ms to evening with 123 ± 13 ms (Fig. 7 , lower left panel; post hoc t-test; first morning vs. first evening: t = 3.9, df = 5, P = 0.012). However, under regular dexamethasone intake no restoration of a pronounced morning inhibition and no significant decrease of CSP over the course of the second day was found, as the CSP duration was 125 ± 12 ms on the second morning and 121 ± 12 ms in the second evening (Fig. 7 , lower right panel; post hoc ttest; first morning vs. second morning: t = 3.6, df = 5, P = 0.016; first evening vs. second morning: t = 0.4, df = 5, P = 0.7; second morning vs. second evening: t = 1.5, df = 5, P = 0.2). Similarly, plasma cortisol concentrations on the first day showed a typical decrease from a morning peak of 192 ± 20 ng/mL to a mean evening value of 59 ± 17 ng/mL (Fig. 7 , upper left panel; post hoc t-tests; first morning vs. first evening: t = 6.5, df = 5, P = 0.001) but were sufficiently suppressed on the second day under dexamethasone with only 7 ± 1 ng/mL in the morning and 5 ± 1 ng/mL in the evening (Fig. 7, upper right panel) . RMTs did not change significantly in both, the third and the fourth control experiments, following CRH infusion and dexamethasone intake, respectively.
Discussion
The results of our study give evidence for a circadian influence on GABA-mediated inhibitory networks in human motor cortex. We found that 2 TMS parameters of cortical inhibition, that is, the duration of CSP and the amount of LICI, progressively decreased over the course of the day. Moreover, the decline of the 2 parameters was positively correlated. However, a correlation with changes in plasma cortisol levels could not be observed.
Both, CSP and LICI, are thought to be linked by being mediated predominantly via activation of the GABA(B) receptor and have shown association in response to pharmacological interventions (Lang et al. 2006; Mohammadi et al. 2006) . However, dissociation of the 2 parameters in another study indicates that LICI and CSP do not reflect identical neuronal processes (McDonnell et al. 2006) . The concept that the CSP (of more than 100 ms) is caused by a long-lasting cortical inhibition mediated by GABA(B) receptors is consistent with . After a full night of sleep, the CSP significantly increased from 156 ± 7 ms (previous evening) to 172 ± 5 ms the next morning (n 5 7). Also, after a night of complete sleep deprivation, the CSP significantly increased from 158 ± 6 ms (previous evening) to 175 ± 9 ms in the morning (n 5 5). Data are given as mean ± SEM. Figure 6 . Intravenous infusion of 100-lg CRH in the evening led to a significant rise of plasma cortisol levels but left the CSP duration unchanged (n 5 5). Mean CSP was 132 ± 7 ms before, 132 ± 7 ms 30 min after, and 132 ± 14 ms 60 min after CRH infusion. Mean plasma cortisol levels significantly increased from 47 ng/mL before CRH infusion to 134 ng/mL at 30 min and to 184 ng/mL at 60 min after CRH infusion. Data are given as mean ± SEM.
the observation that the duration of the inhibitory postsynaptic potentials (IPSPs) elicited by GABA(B) receptor activation is in the range of several hundred milliseconds (Connors et al. 1988 ). Further evidence comes from studies demonstrating that intrathecal administration of the specific GABA(B) receptor agonist baclofen caused a dose-dependent increase in CSP (Siebner et al. 1998 ) and the GABA reuptake inhibitor tiagabine prolonged the CSP (Werhahn et al. 1999) . Tiagabine also increased that amount of LICI (Werhahn et al. 1999) , and it could been shown that a single dose of baclofen increased LICI in healthy subjects (McDonnell et al. 2006) . Accordingly, it was proposed that LICI is also mediated by slow IPSPs via activation of the GABA(B) receptor (Werhahn et al. 1999 ). These results on CSP and LICI are specific, since no other TMS parameter showed any change during the course of the day. This is important because it demonstrates that global parameters of cortical or corticospinal excitability, such as the motor thresholds and I/O curves, which would be altered by changes in vigilance or alertness, were not affected. Also, there was no evidence for changes in any other intracortical inhibitory or facilitatory network, as well as no hint for changes in neuronal membrane excitability.
The findings can be further characterized by the results of the control experiments. The first 2 control experiments were performed to exclude unspecific arousal effects due to repeated TMS measurements or prolonged wakefulness. The fact that cortical inhibition was more pronounced in the morning compared with the previous evening and developed irrespective of sleep or sleep deprivation suggests that the observed decrease and increase of the CSP is linked to circadian mechanisms and makes unspecific influences, for example, from vigilance or alertness, unlikely.
The third control experiment tested whether the observed effects were directly linked to cortisol plasma levels. It showed that CRH infusion in the evening could only elevate plasma cortisol levels to morning values but not increase cortical inhibition. CRH can rapidly increase plasma cortisol levels but does not penetrate the blood brain barrier (Martins et al. 1996) . Therefore, it does not develop effects on the central nervous system directly, and the results suggest that the circadian changes in CSP and LICI are not directly linked to plasma cortisol. However, in the fourth control experiment, we found that changes in CSP duration over the course of the day could be completely suppressed by repeated dexamethasone intake. The low-dose dexamethasone suppression test is commonly used to suppress central CRH release (Holsboer et al. 1980; Carroll et al. 1981) . Before dexamethasone application, TMS measurements replicated the finding from the main experiment with prolonged CSP duration in the morning and a decrease in the evening. On the second day, however, when subjects had taken dexamethasone every 6 h, we could not find high CSP values in the morning and no decrease toward the evening. A likely interpretation is that high dexamethasone levels lead to a negative feedback mechanism on central parts of the hypothalamic-pituitaryadrenal (HPA) axis with reduced CRH, and consecutively adenocorticotropic hormone (ACTH) release, and suggests that the observed changes in cortical excitability could be linked to CRH release in the paraventricular nucleus of the hypothalamus. Alternatively, it might also be speculated whether the abolishment of morning increase of CSP could be due to modification of ACTH release. Interactions between GABAergic neurotransmission and CRH secretion have been demonstrated in vitro and in vivo (Calogero et al. 1988; Cullinan et al. 2008) . Whereas the action of CRH initially appeared to be restricted to regulating ACTH secretion by the pituitary (Vale et al. 1981; Dunn and Berridge 1990) , the discovery of CRH-expressing neurons existing in pathways outside of the hypothalamus led to the realization that CRH's function extended beyond the classical action of a hormone in the HPA axis (Wynn et al. 1984; Heinrichs and De Souza 1999) . It now is apparent that CRH receptors are widely distributed throughout neocortical, limbic, and brainstem regions of the central nervous system (Millan et al. 1986; Dautzenberg and Hauger 2002; Hauger et al. 2003; Bale and Vale 2004) and that brain CRH neurotransmission is critical for behavioral, neuroendocrine, and autonomic functions (Hauger et al. 2006; Gao and Bao 2010) . A large amount of evidence suggests that CRH modulates GABAergic neurones postsynaptically on multiple levels of the central nervous system (Hauger et al. 2006) . However, the precise mechanisms by which CRH modulates activity of GABAergic neurones remain to be elucidated.
A possible limitation of the present study is that the data reflects changes of the excitability of the M1 only. To our knowledge there is currently no evidence for similar modifications in other brain areas. Here, the motor cortex served as a cortical model region, which is accessible by noninvasive stimulation. Such a model comes with advantages and limitations. Similar studies could be done, for example, on the occipital cortex, or with other methods than TMS, such as functional imaging techniques, in the frontal cortex.
The novel insights into the physiological properties of human motor cortex have some important scientific, clinical, and Figure 7 . Suppression of endogenous CRH release by repeated oral dexamethasone intake over 24 h prevented morning inhibition (n 5 6). On the control day before dexamethasone intake (CTRL), a significant decrease of CSP in the course of the day was observed (CSP duration 147 ± 13 ms in the morning to 123 ± 13 ms in the evening). However, under the dexamethasone suppression test (DEX) morning inhibition did not develop and no circadian change in CSP duration was found (CSP duration 125 ± 12 ms in the morning to 121 ± 12 ms in the evening). However, plasma cortisol concentrations on the first day showed a typical decrease from a morning peak of 192 ± 20 ng/mL to a mean evening value of 59 ± 17 ng/mL but were sufficiently suppressed on the second day under dexamethasone with only 7 ± 1 ng/mL in the morning and 5 ± 1 ng/mL in the evening. Data are given as mean ± SEM. methodological implications: First, they can be viewed in the context of neuroplasticity and learning. Experiments in slice preparations reveal that pharmacological activation of the GABA(B) receptor constrains or promotes long-term potentiation (LTP), depending on whether increase of GABA(B) receptor--mediated IPSPs or decrease of presynaptic autoinhibition of GABA(A) receptor--mediated inhibition predominates (Mott et al. 1990; Olpe and Karlsson 1990; Davies et al. 1991; Olpe et al. 1993; Staubli et al. 1999) . In humans, it could be shown by using TMS that the GABA(B) receptor agonist baclofen decreases paired associative stimulation (PAS)--induced LTP-like plasticity in human motor cortex (McDonnell et al. 2006 ). This suggests that increased GABA(B)-mediated IPSPs can prevent the development of LTP and that circumstances with increased GABA(B)-mediated cortical inhibition may have a negative impact on LTPdependent behavioral processes. In the light of the present findings, the question arises whether circadian changes of cortical excitability have an influence on neuroplasticity. Or in other words: do we learn better in the evening-when GABA(B)-mediated inhibition is low?
This concept is further supported by another TMS study that used PAS to induce LTP-like plasticity at different times of the day (Sale et al. 2008) . They compared CSP data before and after PAS obtained in 2 evening sessions, separated by at least 1 week, 1 session with the subjects taking hydrocortisone medication an hour before the TMS tests and 1 session with placebo. Here, PAS-facilitated MEP significantly in the evening but not in the morning, and oral hydrocortisone prevented this facilitation. Sale et al. (2008) also demonstrated longer CSP duration in the morning compared with the evening. The authors concluded that neuroplasticity in the human M1-and GABA(B)-dependent intracortical inhibitory systems are influenced by time of day and modified by circulating levels of cortisol. Our data now extends the picture to the point that probably not cortisol, but CRH modifies cortical excitability over the course of the day.
A discrepancy to the study by Sale et al. is that they found CSP duration was significantly shorter in the placebo compared with the hydrocortisone session. The experiment was not specifically set up to test the effect of cortisone on CSP. Saliva cortisol concentration obtained from the first experiment in this work (morning--evening comparison of PAS effectiveness and pre-PAS CSP duration) did not correlate with pre-PAS CSP duration. Only with exogenous hydrocortisone application this correlation could be found. Therefore, it seems reasonable that the authors focused their interpretation on the statement that neuroplasticity is modified by cortisol, not that cortisol increases CSP duration. In contrast, our experimental set-up was designed to examine the influence of endogenous cortisol (control experiment #3) and CRH (control experiment #4) on CSP as a parameter of cortical inhibition. We found no change in CSP duration despite an approximately 4-fold increase of blood cortisol, but a clear modification of circadian changes of CSP after negative feedback suppression of the central HPAaxis hormones. Perhaps, the few discrepancies of the 2 studies have to be accounted to the different methodological approaches, basically they pursued different questions.
In addition, the present findings are interesting from a clinical perspective. Many neuropsychiatric diseases show circadian fluctuations of their symptomatology: for example, morning depression in affective disorders, awakening seizures in idiopathic-generalized epilepsies (IGE), or restless-leg symptoms in the evening. On the basis of our results, it can be speculated whether these fluctuations may be linked to altered states of cortical excitability. The approach could be used as a diagnostic tool to elucidate pathophysiological properties of these diseases. It might even be helpful to monitor the success of new pharmacological treatment strategies. To our knowledge, circadian effects have not been examined with TMS for affective and movement disorders, so far. For IGE, however, it was shown that in patients with juvenile myoclonic epilepsy (JME), the duration of CSP did not change during the day (179.2 ms in the morning vs. 178.5 ms in the evening), whereas healthy controls had a comparable decrease of the CPS duration as in our study (189.1 ms in the morning vs. 178.1 ms in the evening), even though this difference did not reach significance (Pfutze et al. 2007 ). Could it be that JME patients lack a natural morning inhibition of motor cortex, promoting the occurrence of myoclonic jerks and grand mal seizures? And will antiepileptic pharmacotherapy restore this deficiency? Further research will be necessary to clarify these questions.
Finally, on the methodological issue, when performing studies with repeated TMS measurements it should be considered that some parameters of cortical excitability might not be comparable if tested at different times of the day. This point has so far not been well recognized and only few studies mention the time during the day, when measurements have been performed, at all. Future research using TMS should account for this problem.
In conclusion, we found evidence for a specific modulation of GABAergic motor cortex inhibition within the circadian cycle, possibly linked to CRH. The results may be helpful to understand the pathophysiology of neuropsychiatric disorders with circadian fluctuations of their symptomatology and may reflect a neurobiological basis for different capabilities of developing neuroplasticity over the course of the day.
Notes
